GC Biotherapeutics (GCBT) is a newly established and emerging biopharmaceutical company in Montreal, Canada. A subsidiary of GC (formerly Green Cross), a global healthcare business headquartered in S. Korea, GCBT features the first and only commercial-scale plasma fractionation facility in Canada. With the state-of-the-art biomanufacturing facility, GCBT produces a portfolio of vital biotherapeutic drug products, to treat rare and chronic medical conditions. As a proud member of the Canadian Life Sciences community, we are committed to spearhead the growth of the domestic fractionation industry while continuously evolving our technologies and expertise. GCBT is the headquarters servicing both Canada and the U.S., and our mission brings together our passion and dynamic leadership, while creating innovative solutions for healthier lives around the world. Since 1967, GC specializes in the development and commercialization of plasma derivatives, preventive vaccines, recombinant proteins, and antibodies. For more than half a century in the biopharmaceutical industry, GC acquired unparalleled expertise in plasma manufacturing. As a global leader, we continue to research and develop safer and more effective next-generation products. With its innovative platform for immunity products and protein engineering, GC focuses on resolving the challenges within the specialty pharmaceutical marketplace. By building critical strategic operations throughout the world, GC leads the way in achieving its vision as a global leader in the healthcare industry.